Physician profile
Randall Caviness
NPI 1235140278
$3,816.61
in general payments reported to CMS, 2019-2025
23 companies · $400 in 2025
The $400 reported for 2025 was more than what 81% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $442 · 2021: $821 · 2022: $609 · 2023: $460 · 2024: $513 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,373.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,291.00 | 2021-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $469.44 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $456.85 | 2019-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.68 | 2019-2024 | Jardiance |
| Pfizer INC. | $221.73 | 2019-2022 | |
| Novo Nordisk INC | $192.80 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $180.93 | 2019-2025 | Airsupra |
| Amarin Pharma, INC. | $134.74 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $106.73 | 2019-2022 | |
| Allergan, INC. | $94.12 | 2019-2020 | |
| Orthofix Medical, INC. | $79.20 | 2019 | |
| Sunovion Pharmaceuticals INC. | $61.12 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $53.53 | 2020-2021 | |
| Glaxosmithkline, LLC. | $37.95 | 2019-2024 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $28.00 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.20 | 2022 | |
| Exact Sciences Corporation | $21.52 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $18.20 | 2024 | Dexcom G6 Transmitter |
| Baudax Bio INC. | $17.88 | 2021 | |
| Ironwood Pharmaceuticals, INC | $17.65 | 2020 | |
| Phathom Pharmaceuticals, INC. | $17.52 | 2025 | Voquezna |
| Eisai INC. | $16.60 | 2021 | |
| Daiichi Sankyo INC. | $14.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Caviness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.